LI-RADS 5类与4类和5类联合诊断性能比较:系统评价与Meta分析
该系统评价与Meta分析纳入69项研究、15108个观察对象(9928个(65.7%)为肝细胞癌),比较CT/MRI LI-RADS 5类与4类和5类联合(LR-4/5)对肝细胞癌的诊断性能。联合LR-4/5较LR-5敏感度更高(83.0% vs 65.7%),但特异度(75.0% vs 91.7%)、阳性似然比(3.60 vs 6.18)和阴性似然比(0.22 vs 0.38)均更低,各亚组结果相似。
要点
- 联合LR-4/5较LR-5敏感度提高(83.0% vs 65.7%),特异度降低(75.0% vs 91.7%)。
- 联合LR-4/5较LR-5阳性似然比降低(3.60 vs 6.18),阴性似然比降低(0.22 vs 0.38)。
- 基于CT/MRI LI-RADS 2014、2017或2018版,各亚组结果相似。
核心结论
- 合并LR-4与LR-5可提高敏感度,但降低特异度、阳性似然比和阴性似然比。
- 上述结果可能为管理指南和个体化管理提供参考。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE和EMBASE数据库至2023年1月3日。
- 纳入报告LR-5和联合LR-4/5诊断肝细胞癌性能的研究,使用CT/MRI LI-RADS 2014、2017或2018版。
- 共纳入69项研究、15108个观察对象,其中9928个(65.7%)为肝细胞癌。
- 采用双变量随机效应模型计算合并的每观察对象诊断性能,并按影像模态和MRI对比剂类型进行亚组分析。
诊断标准与关键数值
- 联合LR-4/5 vs LR-5:合并敏感度83.0%(95%CI [80.3-85.8%])vs 65.7%(95%CI [62.4-69.1%]),p < 0.001。
- 联合LR-4/5 vs LR-5:合并特异度75.0%(95%CI [70.5-79.6%])vs 91.7%(95%CI [90.2-93.1%]),p < 0.001。
- 联合LR-4/5 vs LR-5:合并阳性似然比3.60(95%CI [3.06-4.23])vs 6.18(95%CI [5.35-7.14]),p < 0.001。
- 联合LR-4/5 vs LR-5:合并阴性似然比0.22(95%CI [0.19-0.25])vs 0.38(95%CI [0.35-0.41]),p < 0.001。
临床应用与阅片要点
- 联合LR-4/5较LR-5提高敏感度但降低特异度及阳性和阴性似然比,该变化幅度可为管理指南和个体化管理提供参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Computed tomography (CT)/magnetic resonance imaging (MRI) Liver Imaging Reporting and Data System (LI-RADS, LR) category 5 has high specificity and modest sensitivity for diagnosis of hepatocellular carcinoma (HCC). The purpose of this study was to compare the diagnostic performance of LR-5 vs combined LR-4 and LR-5 (LR-4/5) for HCC diagnosis.
METHODS: MEDLINE and EMBASE databases through January 03, 2023 were searched for studies reporting the performance of LR-5 and combined LR-4/5 for HCC diagnosis, using CT/MRI LI-RADS version 2014, 2017, or 2018. A bivariate random-effects model was used to calculate the pooled per-observation diagnostic performance. Subgroup analysis was performed based on imaging modalities and type of MRI contrast material.
RESULTS: Sixty-nine studies (15,108 observations, 9928 (65.7%) HCCs) were included. Compared to LR-5, combined LR-4/5 showed significantly higher pooled sensitivity (83.0% (95% CI [80.3-85.8%]) vs 65.7% (95% CI [62.4-69.1%]); p < 0.001), lower pooled specificity (75.0% (95% CI [70.5-79.6%]) vs 91.7% (95% CI [90.2-93.1%]); p < 0.001), lower pooled positive likelihood ratio (3.60 (95% CI [3.06-4.23]) vs 6.18 (95% CI [5.35-7.14]); p < 0.001), and lower pooled negative likelihood ratio (0.22 (95% CI [0.19-0.25]) vs 0.38 (95% CI [0.35-0.41]) vs; p < 0.001). Similar results were seen in all subgroups.
CONCLUSIONS: Our meta-analysis showed that combining LR-4 and LR-5 would increase sensitivity but decrease specificity, positive likelihood ratio, and negative likelihood ratio. These findings may inform management guidelines and individualized management.
CLINICAL RELEVANCE STATEMENT: This meta-analysis estimated the magnitude of changes in the sensitivity and specificity of imaging criteria when LI-RADS categories 4 and 5 were combined; these findings can inform management guidelines and individualized management.
KEY POINTS: There is no single worldwide reporting system for liver imaging, partly due to regional needs. Combining LI-RADS categories 4 and 5 increased sensitivity and decreased specificity and positive and negative likelihood ratios. Changes in the sensitivity and specificity of imaging criteria can inform management guidelines and individualized management.
引用
- Lee S, Kim YY, Shin J, et al. Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis. Eur Radiol. 2024. PMID: 38809263. doi:10.1007/s00330-024-10813-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。